China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd, trading as Asieris Pharma (SHA: 688176), has announced the issuance of the first prescription for its generic version of the UK pharmaceutical major GSK’s (NYSE: GSK) Votrient (pazopanib) in China. This milestone not only marks the entry of a new treatment option for advanced renal cell carcinoma but also signifies Asieris Pharma’s first foray into commercialized products.
First-Line Treatment for Renal Cell Carcinoma
Pazopanib, a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), is recognized as a crucial first-line treatment for advanced renal cell carcinoma. Initially approved in the United States in 2009, the drug’s rights were transferred to Swiss pharmaceutical giant Novartis through an asset swap deal with GSK in 2014. The originator drug gained approval in China in 2017, and since then, other generics by Qilu Pharma, Chia Tai Tianqing, and Chuangnuo Pharma have also entered the Chinese market.
Market Impact and Commercial Strategy
Asieris Pharma’s entry into the market with a generic version of Votrient is expected to increase accessibility and affordability for patients in China, offering a vital first-line treatment option for those battling advanced renal cell carcinoma. This strategic move by Asieris Pharma to commercialize its first product underscores the company’s commitment to expanding its presence in the oncology space and enhancing patient care through affordable medication options.-Fineline Info & Tech
